Medicare's 2026 Drug Price Cuts: A Simple Guide to Your Savings

The core idea is simple: Medicare, as a massive buyer, now has the power to haggle over the price of the most expensive brand-name drugs. For the first time, the government can say, "We'll pay you this much for your drug, not a penny more." This is the business logic behind the Inflation Reduction Act's new program, and it starts in 2026.

Here's how it works in practice. The law targets drugs that are both extremely costly and have no generic or biosimilar competition. For 2026, the first group of ten such drugs was selected. The goal was clear: to set a new, lower baseline price. The result? A minimum discount of 38% off the 2023 list price. This isn't just a suggestion; it's a new floor that drugmakers must meet to keep their drugs in Medicare's formulary.

The process itself is a negotiation. The Centers for Medicare & Medicaid Services (CMS) didn't just hand out a take-it-or-leave-it offer. They engaged in good-faith talks with each company, exchanging initial offers and counteroffers. In many cases, companies lowered their prices to reach an agreement, while CMS also adjusted its offers upward during discussions. For five drugs, a deal was struck through this back-and-forth. For the other five, CMS issued a final offer that the companies accepted. The bottom line is a new price that benefits the entire Medicare program.

The savings are substantial. These ten drugs accounted for a huge slice of spending in 2023-$56.2 billion in total Part D gross covered prescription drug costs, or about 20% of the program's total. If the new negotiated prices had been in place that year, they would have saved the Medicare program an estimated $6 billion per year. That's the program's savings. For you, the beneficiary, the savings show up as lower out-of-pocket costs, with an estimated $1.5 billion in annual savings directly for people with Medicare.

So, the "deal" is a two-step process. First, Medicare negotiates a lower, mandatory price for these blockbuster drugs. Second, your final cost depends on your specific Part D plan's rules for copays and deductibles. The negotiated price sets the new baseline, but your plan's structure determines how much you pay from your pocket. It's a powerful shift in leverage for the largest buyer of prescription drugs.

The 10 Drugs: What They Are and Who Uses Them

The policy change isn't abstract. It targets a specific group of blockbuster medications that treat serious, often lifelong conditions. The first ten drugs selected for negotiation in 2026 are: Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and NovoLog. These are not niche products; they are among the most prescribed and expensive drugs in the Medicare system.

The scale of spending is what made them the target. In 2022, Medicare's Part D program spent a staggering $46.4 billion on just these ten drugs. That figure represented nearly one-fifth of all Part D spending that year, or about 19%. For beneficiaries, the out-of-pocket cost was still substantial, at $3.4 billion. This concentration of spending on a small group of drugs is exactly the leverage point the law was designed to exploit.

Who uses these drugs? The answer is millions of Americans managing chronic, high-cost conditions. These medications treat blood clots (Eliquis, Xarelto), type 2 diabetes (Jardiance, Januvia, Farxiga), heart failure (Entresto), autoimmune diseases like rheumatoid arthritis (Enbrel, Stelara), cancer (Imbruvica), and insulin-dependent diabetes (NovoLog). The program covers nearly 9 million Medicare beneficiaries who rely on these treatments.

The law's impact goes beyond just lowering prices. It also mandates that all Part D plans must cover these drugs, including all dosages and forms. This requirement is already improving access. Analysis shows that for several forms of nine of the first ten drugs, coverage rates have expanded since the rule took effect. For instance, coverage for the insulin product NovoLog and two dosages of Imbruvica has grown significantly. This means more people with Medicare will have reliable access to these essential medicines, regardless of their specific plan. The savings from the price cuts will flow directly to the program and, ultimately, to the pockets of the patients who use them.

Your Savings: Navigating the Plan Maze

The new negotiated prices are a powerful floor, but your final bill at the pharmacy depends on the specific plan you choose. All Part D plans must cover these ten drugs, but their cost-sharing rules-copays, coinsurance, and deductibles-can vary widely. This is where your savings strategy begins.

Think of the negotiated price as the wholesale cost of the drug. Your plan's structure is the markup and service fee you pay on top. For instance, a plan might have a $0 deductible, which is ideal, or one capped at $615 in 2026. After that deductible is met, you typically pay 25% of the cost through the initial coverage stage until your out-of-pocket spending hits $2,100. After that, you enter catastrophic coverage and pay very little for the rest of the year. The key is to compare how different plans handle these stages for your specific drugs.

Your monthly premium is another major variable. While a low premium can save you money upfront, it might come with higher copays or coinsurance later. Conversely, a higher-premium plan might offer lower drug costs. The rule of thumb is to look at your total annual drug spending, not just the monthly fee. If you take a drug like Eliquis or Januvia every day, a plan with a higher premium but a $0 copay could save you hundreds or thousands of dollars over the year. The bottom line is that you must shop and compare.

Don't overlook extra help. If your income is limited, you may qualify for the Extra Help program, which can dramatically reduce or even eliminate your premiums, deductibles, and copays. This is a critical step to maximize your savings. You can also check if you're eligible for Medicaid, which can provide additional support.

Finally, remember that coverage for these drugs has improved. For several forms of nine of the ten drugs, including insulin products and cancer drugs, coverage rates have expanded since the new rules took effect. This means you're more likely to find your specific drug on your plan's formulary, but you still need to confirm it's there and understand the cost-sharing details. The savings are real, but they require a bit of homework to claim.

Risks, Limits, and What to Watch

The program is a major step forward, but it has clear boundaries and a path ahead. Understanding these practical limits and upcoming milestones is key to navigating the savings.

First, the program's reach is limited. It only targets the most expensive, brand-name drugs with no competition. This means drugs for certain rare diseases or niche conditions are excluded. For beneficiaries who rely on these medications, the cost burden remains high. The savings flow to the Medicare program and to those using the blockbuster drugs on the list, but not to everyone.

The rollout is also phased. The first ten drugs were negotiated for 2026. A second, larger group of 15 high-cost drugs will have their prices set in 2027. This expansion means the full impact of the law will unfold over the next few years. For now, the savings are concentrated on a specific, high-spending group.

For beneficiaries, the most important thing to watch is the details of your plan. The negotiated price sets a new baseline, but your final cost depends on your plan's rules. As the program rolls out, monitor updates to your plan's formulary and cost-sharing details. Coverage for these drugs has already improved, but you must confirm your specific drug and dosage are still covered and understand any changes to copays or deductibles.

Finally, timing matters. The best time to enroll in a Part D plan for the first time is during your Initial Enrollment Period. Delaying can trigger a late enrollment penalty, which is added to your monthly premium. This penalty can erode your savings, especially if you have a low-premium plan. Even if you don't take many drugs now, getting coverage early avoids this penalty and ensures you're protected when you need it.

The bottom line is that while the program delivers real savings for a major group of drugs, it's not a cure-all. It has defined limits, a multi-year rollout, and requires beneficiaries to stay informed and proactive about their plan choices.